IHE iShares U.S. Pharmaceuticals ETF
Quote as of Oct 09, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 98.86 | Day Range | 98.35 – 100.41 |
| 52-Week Range | 72.94 – 108.66 | Volume | 342.36K |
| Avg Volume | 247.45K | AUM | $1.55B (Oct 12, 2026) |
| Expense Ratio | 0.37% | Yield (TTM) | 1.43% |
| NAV | 100.15 | Premium/Discount | -0.06% indicative |
| Inception | May 01, 2006 | Holdings | 53 |
| Issuer | iShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 464288836 | ISIN | US4642888360 |
| Management | Not stated in source data | ||
About this ETF
The iShares U.S. Pharmaceuticals ETF is designed to replicate the investment performance of a benchmark index. This index consists solely of equity securities from pharmaceutical companies operating within the United States.
Description from the fund data provider · profile as of Oct 12, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -2.06% | -0.42% | +14.85% | +17.99% | +32.43% | +18.69% | +10.26% | +7.34% | +9.14% |
| Total return | -2.06% | -0.42% | +15.19% | +18.73% | +34.17% | +20.48% | +12.07% | +8.96% | +10.72% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Oct 09, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.37% | Annual cost of a $10,000 investment | $37.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Oct 11, 2026 · portfolio reporting date from the data provider; holdings are not live positions. 56 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | ELI LILLY | LLY | 24.14% | 316.13K | $369.7M |
| 2 | JOHNSON & JOHNSON | JNJ | 22.28% | 1.33M | $341.3M |
| 3 | PFIZER | PFE | 4.65% | 2.56M | $71.2M |
| 4 | ZOETIS INC CLASS A | ZTS | 4.63% | 969.56K | $70.9M |
| 5 | VIATRIS | VTRS | 4.55% | 4.00M | $69.7M |
| 6 | MERCK & CO INC | MRK | 4.48% | 481.80K | $68.6M |
| 7 | ROYALTY PHARMA PLC CLASS A | RPRX | 4.30% | 1.17M | $65.9M |
| 8 | BRISTOL MYERS SQUIBB | BMY | 4.29% | 1.10M | $65.7M |
| 9 | JAZZ PHARMACEUTICALS PLC | JAZZ | 3.28% | 225.96K | $50.3M |
| 10 | CORCEPT THERAPEUTICS | CORT | 2.56% | 331.12K | $39.3M |
| 11 | ELANCO ANIMAL HEALTH | ELAN | 2.56% | 1.74M | $39.2M |
| 12 | AXSOME THERAPEUTICS | AXSM | 1.72% | 154.98K | $26.4M |
| 13 | LIGAND PHARMACEUTICALS | LGND | 1.34% | 69.39K | $20.5M |
| 14 | DEFINIUM THERAPEUTICS INC | DFTX | 1.04% | 467.70K | $16.0M |
| 15 | INDIVIOR PHARMACEUTICALS INC | INDV | 0.95% | 410.79K | $14.6M |
| 16 | VERADERMICS | MANE | 0.90% | 109.07K | $13.8M |
| 17 | AMNEAL PHARMACEUTICALS INC CLASS A | AMRX | 0.82% | 642.54K | $12.6M |
| 18 | ORGANON | OGN | 0.82% | 914.09K | $12.6M |
| 19 | EDGEWISE THERAPEUTICS | EWTX | 0.73% | 283.52K | $11.1M |
| 20 | AMYLYX PHARMACEUTICALS | AMLX | 0.64% | 358.24K | $9.7M |
| 21 | TARSUS PHARMACEUTICALS | TARS | 0.63% | 134.41K | $9.7M |
| 22 | ENLIVEN THERAPEUTICS | ELVN | 0.59% | 221.88K | $9.0M |
| 23 | SUPERNUS PHARMACEUTICALS | SUPN | 0.56% | 202.34K | $8.5M |
| 24 | PRESTIGE CONSUMER HEALTHCARE | PBH | 0.52% | 164.96K | $7.9M |
| 25 | LIQUIDIA | LQDA | 0.47% | 258.60K | $7.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.43% | Paid (last 12 months) | $1.4334 |
| Frequency | Quarterly | SEC yield | Not provided by our data source; see the issuer page |
| Last ex-date | Sep 15, 2026 | Last payment | $0.2789 (Sep 18, 2026) |
| Growth 1Y | +27.82% | Growth 3Y / 5Y (ann.) | -25.75% / -11.99% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Sep 15, 2026 | Sep 15, 2026 | Sep 18, 2026 | $0.2789 |
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.2848 |
| Mar 17, 2026 | Mar 17, 2026 | Mar 20, 2026 | $0.2845 |
| Dec 16, 2025 | Dec 16, 2025 | Dec 19, 2025 | $0.5853 |
| Sep 16, 2025 | Sep 16, 2025 | Sep 19, 2025 | $0.3124 |
| Jun 16, 2025 | Jun 16, 2025 | Jun 20, 2025 | $0.3065 |
| Mar 18, 2025 | Mar 18, 2025 | Mar 21, 2025 | $0.2917 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 20, 2024 | $0.2108 |
| Sep 25, 2024 | Sep 25, 2024 | Sep 30, 2024 | $0.3589 |
| Jun 11, 2024 | Jun 11, 2024 | Jun 17, 2024 | $0.2940 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 27, 2024 | $0.2750 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.4042 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 17.82% / 17.13% | Sharpe 1Y / 3Y | 1.99 / 1.07 |
| Max drawdown 1Y / 3Y | -9.19% / -15.92% | Sortino 1Y | 3.35 |
| Beta vs S&P 500 (3Y) | 0.483 | Correlation vs S&P 500 (1Y) | 0.247 |
| Downside deviation 1Y | 10.59% | Risk-free rate used | 4.05% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Oct 12, 2026. Formulas →
Liquidity
| Volume today | 342.36K | Average volume | 247.45K |
| AUM | $1.55B | Premium/Discount | -0.06% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV: an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $28.8M | +1.89% | $1.52B → $1.55B |
| 1 Month | -$52.1M | -3.22% | $1.62B → $1.55B |
| 1 Week | -$81.4M | -5.08% | $1.60B → $1.55B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source; review them before investing.
Latest News for IHE
No articles mention this fund directly in the last 7 days; showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.